Lonza clarified its reported position, inPharma Technologist, with regard to its joint venture with Teva. A recent interview with Lonza's CEO had led writers to imply that Lonza was rethinking its position on biosimilars -- and presumably its JV with Teva to produce biosimilar drugs. This was largely caused (according to these articles) by FDAs less than clear guidance on a biosimilar pathway, and the resultant uncertainty to the biosimilar economic models that had been developed circa 2009.
Lonza moved to quash this notion today by reaffirming its intent to produce biosimilars as stated previously through the Teva connection. Lonza will however review its assumptions around the economic models for biosimilars -- particularly in the US market.
"Biosimilars remain an attractive market opportunity and both parties stay fully committed to the TL collaboration," said a Lonza spokesman.
Posted by Bruce Lehr Apr 3rd 2013.